- Home
- IMMX vs DOMH Comparison
IMMX vs DOMH Comparison
Compare IMMX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- DOMH
- Stock Information
- Founded
- IMMX 2014
- DOMH 1967
- Country
- IMMX United States
- DOMH United States
- Employees
- IMMX N/A
- DOMH N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- DOMH Health Care
- Exchange
- IMMX Nasdaq
- DOMH Nasdaq
- Market Cap
- IMMX 82.6M
- DOMH 74.0M
- IPO Year
- IMMX 2021
- DOMH N/A
- Fundamental
- Price
- IMMX $3.28
- DOMH $5.48
- Analyst Decision
- IMMX Strong Buy
- DOMH
- Analyst Count
- IMMX 1
- DOMH 0
- Target Price
- IMMX $8.00
- DOMH N/A
- AVG Volume (30 Days)
- IMMX 769.8K
- DOMH 176.3K
- Earning Date
- IMMX 11-07-2025
- DOMH 11-10-2025
- Dividend Yield
- IMMX N/A
- DOMH 9.89%
- EPS Growth
- IMMX N/A
- DOMH N/A
- EPS
- IMMX N/A
- DOMH 9.19
- Revenue
- IMMX N/A
- DOMH $99,588,000.00
- Revenue This Year
- IMMX N/A
- DOMH N/A
- Revenue Next Year
- IMMX N/A
- DOMH N/A
- P/E Ratio
- IMMX N/A
- DOMH $0.54
- Revenue Growth
- IMMX N/A
- DOMH 691.07
- 52 Week Low
- IMMX $1.34
- DOMH $0.83
- 52 Week High
- IMMX $4.05
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- IMMX 55.27
- DOMH 49.26
- Support Level
- IMMX $2.85
- DOMH $4.31
- Resistance Level
- IMMX $3.53
- DOMH $4.92
- Average True Range (ATR)
- IMMX 0.38
- DOMH 0.41
- MACD
- IMMX -0.07
- DOMH 0.00
- Stochastic Oscillator
- IMMX 34.80
- DOMH 61.32
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.